

HOUSTON
Methodist
CANCER CENTER

August 1, 2020

RE: Notice of Award

Drs. Maen Abdelrahim and Stephen Safe,

On behalf of the Houston Methodist Cancer Center, we are pleased to inform you that your proposal "Nuclear Receptor 4A1 (NR4R1) Antagonists as Immunotherapy Mimics for Targeting PD-L1 in Colon Cancer" has been accepted for the 2020 Research Innovation Award.

This award is \$100,000 for 2 years (\$50,000 per year, contingent upon a successful progress report). The year 1 project period is from August 1, 2020 until July 31, 2021. As a reminder, the funds cannot be used for capital equipment, PI salary support, indirect or subcontract costs; no cost sharing or matching is available or required; and any funds not expended during the project period will not carry over. The first year, two-page progress report will be due on the last day of the project period.

A Project ID will be set-up for this project and will require one lead PI (Dr. Abdelrahim) from Houston Methodist as the award recipient; the lead PI will be asked to submit the progress report, and is asked to oversee and ensure the appropriate level of funding to the other principal investigators named on this proposal. A subcontract is needed for any funds being used at Texas A&M University (TAMU), for which we will begin the process of establishing the subcontract with our Contracts Office. Please confirm the amount to be directed to TAMU for year 1. Lastly, we ask that you acknowledge the Houston Methodist Cancer Center for any publications that arise from this award.

If you have any questions related to this award, please feel free to contact Johnique Atkins, Program Project Manager (jtatkins@houstonmethodist.org), or Tamim Malbari, Research Administrator (tsmalbari@houstonmethodist.org).

Congratulations on your accomplishment.

Houston Methodist Cancer Center Research Innovation Award Committee